Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TytoCare Raises $50M Amid Rising Demand To Remotely Monitor COVID-19 Patients

Executive Summary

TytoCare will use the $50m it raised in a funding round to expand the reach of its telehealth solutions.

You may also be interested in...



Tyto Care Raises $50M In Series D To Expand Telehealth Platform

Tyto Care will use the proceeds to expand its telehealth and remote monitoring solution to the US, Europe, and Asia, and add AI capabilities.   

BIO Digital: Investment Panel Sees Continued Rising Adoption Of Telehealth, Remote Monitoring

BIO Digital investment panel sees strong investment opportunities in telehealth, remote monitoring and converging digital products.

Post-Pandemic World: Former VA Secretary Predicts Acceleration In Telemedicine, Digitalization, Hospital Redesign

Former VA Secretary David Shulkin said health care post-COVID-19 requires a makeover with greater hospital integration and ongoing telemedicine to address behavioral and physical issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT126560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel